Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an update.
Chimeric Therapeutics Limited has announced a non-renounceable entitlement offer to raise approximately $3.2 million. The funds will primarily support the development of their CHM CDH17 Phase 1/2 clinical trial and the CORE-NK program. The offer includes new shares and options at a discounted price, with the proceeds also aiding general working capital and costs associated with the capital raising. This move is expected to enhance Chimeric’s operational capabilities and strengthen its position in the biotechnology sector.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is a biotechnology company focused on developing innovative cell therapies for cancer treatment. The company is engaged in clinical trials for its CHM CDH17 CAR-T program targeting neuroendocrine tumors, colorectal cancer, and gastric cancer, as well as its CORE-NK platform in collaboration with Case Western University and MD Anderson Cancer Centre.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$7.98M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.